Annual chlamydia and gonorrhoea testing among participants attending selected clinics of the OHTN Cohort Study, 2008–2011
| 2008 | 2009 | 2010 | 2011 | |
|---|---|---|---|---|
| Per cent tested for chlamydia/gonorrhoea* | ||||
| All† | 15.2 (13.7 to 16.7) | 20.5 (19.0 to 22.1) | 24.1 (22.5 to 25.7) | 27.0 (25.3 to 28.6) |
| MSM† | 18.6 (16.6 to 20.6) | 23.9 (22.0 to 25.8) | 28.9 (26.9 to 30.9) | 32.4 (30.3 to 34.4) |
| Non-MSM male† | 3.7 (1.5 to 6.0) | 5.6 (3.0 to 8.2) | 6.9 (4.1 to 9.7) | 10.1 (6.8 to 13.4) |
| Women† | 10.3 (7.1 to 13.4) | 17.5 (13.8 to 21.1) | 17.5 (14.0 to 20.9) | 18.5 (15.0 to 22.0) |
| Chlamydia positivity rate‡ | ||||
| All | 5.5 (4.6 to 8.1) | 4.7 (3.9 to 6.4) | 4.8 (4.0 to 6.4) | 3.6 (2.9 to 5.0) |
| MSM | 6.1 (4.9 to 9.0) | 5.4 (4.4 to 7.4) | 5.4 (4.4 to 7.2) | 3.7 (2.8 to 5.2) |
| Non-MSM male | 0.0 (0.0 to 36.9) | 0.0 (0.0 to 21.7) | 0.0 (0.0 to 16.8) | 3.1 (0.1 to 17.4) |
| Women | 2.8 (0.1 to 15.5) | 1.4 (0.0 to 7.6) | 2.5 (0.3 to 9.0) | 3.5 (0.7 to 10.1) |
| Proportion diagnosed with chlamydia§ | ||||
| All | 0.8 (0.5 to 1.8) | 1.0 (0.6 to 1.8) | 1.2 (0.8 to 2.0) | 1.0 (0.6 to 1.7) |
| MSM | 1.1 (0.6 to 2.4) | 1.3 (0.8 to 2.3) | 1.5 (1.0 to 2.6) | 1.2 (0.7 to 2.1) |
| Non-MSM male | 0.0 (0.0 to 1.4) | 0.0 (0.0 to 1.2) | 0.0 (0.0 to 1.2) | 0.3 (0.0 to 1.8) |
| Women | 0.3 (0.0 to 1.3) | 0.2 (0.0 to 1.3) | 0.4 (0.1 to 1.6) | 0.6 (0.1 to 1.9) |
| Gonorrhoea positivity rate‡ | ||||
| All | 5.4 (2.9 to 7.8) | 2.9 (1.5 to 4.3) | 2.7 (1.5 to 4.0) | 3.0 (1.8 to 4.2) |
| MSM | 5.5 (2.8 to 8.2) | 3.5 (1.8 to 5.2) | 3.2 (1.8 to 4.7) | 3.6 (2.1 to 5.1) |
| Non-MSM male | 10.0 (0.3 to 55.7) | 0.0 (0.0 to 21.7) | 0.0 (0.0 to 17.6) | 0.0 (0.0 to 11.5) |
| Women | 3.0 (0.1 to 16.9) | 0.0 (0.0 to 5.1) | 0.0 (0.0 to 4.8) | 0.0 (0.0 to 4.3) |
| Proportion diagnosed with gonorrhoea§ | ||||
| All | 0.7 (0.4 to 1.1) | 0.6 (0.3 to 0.9) | 0.6 (0.4 to 0.9) | 0.8 (0.5 to 1.1) |
| MSM | 1.0 (0.5 to 1.5) | 0.8 (0.4 to 1.2) | 0.9 (0.5 to 1.3) | 1.1 (0.7 to 1.6) |
| Non-MSM male | 0.4 (0.0 to 1.7) | 0.0 (0.0 to 1.2) | 0.0 (0.0 to 1.2) | 0.0 (0.0 to 1.2) |
| Women | 0.3 (0.0 to 1.3) | 0.0 (0.0 to 0.9) | 0.0 (0.0 to 0.8) | 0.0 (0.0 to 0.8) |
Results shown as percentages with 95% CIs in parentheses.
*Virtually all (99%) tests were simultaneously co-tested for both pathogens.
†Statistically significant increase from 2008–2011 (p<0.05). ‡The positivity rate is the per cent with a reactive test among all tested in that year.
§The proportion diagnosed is the per cent with a reactive test among all patients in care and under observation in that year.
MSM, men who have sex with men.